Home » Authors » Don Long

Articles by Don Long

‘D’ $42.2M will back Calypso’s launch of localization system

Jan. 11, 2007

Boston Scientific to cut 500-600 from CRM unit, formerly Guidant

Jan. 10, 2007

‘D’ $42.2M will back Calypso’s launch of localization system

Jan. 9, 2007

Grow-your-own valves possible via stem cells?

Jan. 1, 2007

Americans too often on losing side of risk/benefit ratio

Jan. 1, 2007

BB&T — 29, and counting

Jan. 1, 2007

Deals roundup: MIVT acquiring stent platform with buy of Biosync Scientific

Dec. 12, 2006

Financings roundup: Galil adds $52M in financing and completes Oncura deals

Dec. 12, 2006

Closing loop' for 'holy grail' of diabetes is more than devices

Dec. 7, 2006

SilverHawk to NightHawk is next big step for FoxHollow

Dec. 7, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...